23 Jul, 2026
According to Straits Research the global precision cardiology market size was valued at $15.77 billion in 2025 and is projected to grow from $17.78 billion in 2026 to $46.45 billion by 2034, at a CAGR of 12.75% during the forecast period 2026–2034.
According to healthcare experts, precision cardiology is a rapidly increasing market. Demand for early screening and sequencing rises as cardiovascular disease prevalence rises.
Precision cardiologists adopt a multidisciplinary approach to treating and preventing cardiovascular disease by considering genetics, lifestyle, and environmental exposures. Instead of using a single route phenotype for all patients with the same symptoms, this technique considers each patient's unique traits.
Precision cardiology is witnessing a growth spurt because to the rising prevalence of cardiovascular disease, the emphasis on early disease screening, and the falling cost of sequencing technologies. Precision cardiology tests based on cutting-edge sequencing technologies may help doctors make better cardiovascular care decisions. Researchers can employ better precision cardiology tests to uncover novel genetic biomarkers for cardiovascular disease and create new treatments. Precision cardiology market growth is fueled by academic and research institutions' use of research-based products and growing and legacy firms' investments.
Age, sedentary behavior, poor eating habits, diabetes, cigarette use, and family history all contribute to the high prevalence of cardiovascular disease. Over 659,000 Americans die annually from heart disease, according to the CDC. Over 4 million Australians have cardiovascular disease, according to the Heart Foundation (CVD). European Heart Network: 3.9 million Europeans die annually from cardiovascular disease.
First, enhance diagnosis to reduce CVDs. CVDs, especially inherited heart problems, are growing more complex. New diagnostic tools are needed to support patients and doctors. Hospitals and diagnostic labs use molecular diagnostics to evaluate CVDs for better clinical insights and early treatment solutions. This drives the global precision cardiology market.
Decreasing sequencing study costs and increased public awareness of the importance of early identification for cardiovascular disorders boost the global precision cardiology market (CVDs). In 2019, cardiovascular disease (CVD) will account for 31% of global deaths.
Plaque in arteries impedes blood flow. This reduces heart muscle oxygen. Heart disease kills more U.S. men and women. Early heart disease screenings are crucial. Prevention is important no matter your symptoms or risk factors. American Heart Association recommends cardiovascular screening at 20. (AHA). Without a high-risk patient, screening findings can motivate you to improve your health.
Due to tremendous technical developments and huge organizations’ embrace of these advancements, the global precision cardiology market is one of the most promising prospects for precision care companies. Large organizations have simultaneously adopted these rapid technical developments. This is because several new companies are providing reliable cardiac genetic testing goods and services. This sector is growing quickly to standardize healthcare. Market juggernauts and new, inventive enterprises will contribute to this industry's quick expansion and explore new chances globally.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa make up the Precision Cardiology Market.
North America leads the global precision cardiology market in revenue. This is due to key market participants in the U.S. and the growing acceptance of technologically upgraded products and services in clinical and research environments.
Precision cardiology has the largest share in North America due to market leaders like Laboratory Corporation of America Holdings, Illumina, Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc. and Quest Diagnostics Incorporated, as well as the adoption of high-fidelity precision cardiology tests to diagnose cardiovascular diseases. Due to these factors, the North American precision cardiology market should increase. Government efforts to integrate genetic biomarkers and cardiovascular care have impacted the regional sector.
Asia-Pacific will have the greatest CAGR from 2022 to 2030. Increased cardiovascular disease prevalence, better healthcare understanding, and a stable economy have led to more research and precision cardiology testing.
sales@straitsresearch.com